Seizure outcomes in patients with anti‐<scp>NMDAR</scp>encephalitis: A follow‐up study

  • Xu Liu
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Bo Yan
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Rui Wang
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Chen Li
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Chu Chen
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Dong Zhou
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China
  • Zhen Hong
    Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China

説明

<jats:title>Summary</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the long‐term seizure outcome and potential factors associated with seizure outcome in patients with anti‐<jats:italic>N</jats:italic>‐methyl‐<jats:sc>d</jats:sc>‐aspartate receptor (anti‐<jats:styled-content style="fixed-case">NMDAR</jats:styled-content>) encephalitis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In the setting of a prospective, single‐center, longitudinal cohort study, 109 patients were evaluated with ongoing follow‐up. Patients underwent clinical evaluation every 3 months. Seizure outcomes and the potential risk factors were assessed with a median follow‐up of 24 months (6–60 months).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 109 patients (47 men; 62 women) with anti‐<jats:styled-content style="fixed-case">NMDAR</jats:styled-content>encephalitis, 88 patients (80.7%) had reported seizures at acute phase, including single seizure (17/88, 19.3%), repetitive seizures (27/88, 30.7%), nonrefractory status epilepticus (22/88, 25%), refractory status epilepticus (SE; 13/88, 14.8%), and super refractory status epilepticus (9/88, 10.2%). Seizure was more likely to recur in patients with tumor presence, status epilepticus (<jats:styled-content style="fixed-case">SE</jats:styled-content>) development, coma, or<jats:styled-content style="fixed-case">intensive care unit (ICU</jats:styled-content>) admission in the acute phase (p < 0.05). Seizure freedom was achieved within 2 years in all patients. More than 80% of the whole cohort with acute seizures had their last seizure within 6 months of disease onset.</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>Seizure is a common feature in the acute stage of anti‐<jats:styled-content style="fixed-case">NMDAR</jats:styled-content>encephalitis but not thereafter. The presence of tumor,<jats:styled-content style="fixed-case">SE</jats:styled-content>, coma, and/or<jats:styled-content style="fixed-case">ICU</jats:styled-content>admission in the acute phase predicts early seizure occurrence after the acute phase. Seizure freedom was typically achieved in our follow‐up, and long‐term use of antiepileptic drugs may not be necessary.</jats:p></jats:sec>

収録刊行物

  • Epilepsia

    Epilepsia 58 (12), 2104-2111, 2017-11-03

    Wiley

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ